

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH ATRIAL FIBRILLATION

1. **Stroke Prevention in Atrial fibrillation.** *Thrombosis Canada.* Thrombosis Canada; 2017.
2. AA Pharma Inc: **Nadolol.** In: *CA Product Monograph.* Vaughan, ON; 2016.
3. Aarnoudse AJ, Dieleman JP, Visser LE, Arp PP, van der Heiden IP, van Schaik RH, Molokhia M, Hofman A, Uitterlinden AG, Stricker BH: **Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration.** *Pharmacogenetics and genomics* 2008, **18**(4):299-305.
4. Actavis Pharma Inc: **Propranolol** In: *US Product Monograph.* Parsippany, NJ; 2016.
5. Actavis Pharma Inc: **Cartia XT (diltiazem).** In: *US Product Monograph.* Fort Lauderdale, FL 2017.
6. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G: **Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.** *Chest* 2012, **141**(2 Suppl):e44S-88S.
7. Almatica Pharma Inc: **Tenormin (atenolol).** In: *US Product Monograph.* Pine Brook, NJ; 2017.
8. Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, Robinson M, Barton S, Brunisholz K, Mower CP *et al.*: **A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).** *Circulation* 2012, **125**(16):1997-2005.
9. Andrade JG, Verma A, Mitchell LB, Parkash R, Leblanc K, Atzema C, Healey JS, Bell A, Cairns J, Connolly S *et al.*: **2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation.** *The Canadian journal of cardiology* 2018, **34**(11):1371-1392.
10. ANI Pharmaceuticals Inc: **Inderal (propranolol hydrochloride).** In: *US Product Monograph.* Baudette, MN; 2018.
11. Aphenia Pharma Solutions: **Toprol XL (metoprolol succinate)** In: *US Product Monograph.* Tennessee, Llc; 2018.
12. Apotex Inc: **Apo-Bisoprolol.** In: *CA Product Monograph.* Toronto, ON; 2017.
13. Apotex Inc: **Diltiaz (diltiazem hydrochloride)** In: *CA Product monograph.* Toronto, ON; 2018.
14. Aralez Pharmaceuticals US Inc: **Toprol XL (metoprolol succinate).** In: *US Product Monograph.* Princeton, NJ; 2016.
15. Aralez Pharmaceuticals US Inc: **Metoprolol succinate.** In: *US Product Monograph.* Aralez Pharmaceuticals; 2016.

16. AstraZeneca Canada Inc: **Tenormin (atenolol)**. In: *CA Product Monograph*. Mississauga, ON; 2016.
17. AstraZeneca Canada Inc: **Tenormin (atenolol)**. In: *CA Product Monograph*. Mississauga, ON; 2017.
18. Batty JA, Hall AS, White HL, Wikstrand J, de Boer RA, van Veldhuisen DJ, van der Harst P, Waagstein F, Hjalmarson A, Kjekshus J *et al*: **An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy**. *Clinical pharmacology and therapeutics* 2014, **95**(3):321-330.
19. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Jung B, Lancellotti P, Lansac E, Munoz DR *et al*: **2017 ESC/EACTS Guidelines for the Management of Valvular Heart Disease**. *Revista espanola de cardiologia (English ed)* 2018, **71**(2):110.
20. Bavishi C, Khan AR, Ather S: **Digoxin in patients with atrial fibrillation and heart failure: A meta-analysis**. *International journal of cardiology* 2015, **188**:99-101.
21. Bayer Inc: **Xarelto (rivaroxaban)**. In: *CA Product Monograph*. Mississauga, ON; 2018.
22. BGP Pharma ULC: **Isoptin SR (verapamil hydrochloride)**. In: *CA Product Monograph*. Etobicoke, ON; 2016.
23. Bijl MJ, Visser LE, van Schaik RH, Kors JA, Wittteman JC, Hofman A, Vulto AG, van Gelder T, Stricker BH: **Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users**. *Clinical pharmacology and therapeutics* 2009, **85**(1):45-50.
24. Blake CM, Kharasch ED, Schwab M, Nagele P: **A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics**. *Clinical pharmacology and therapeutics* 2013, **94**(3):394-399.
25. Brieger D, Amerena J, Attia JR, Bajorek B, Chan KH, Connell C, Freedman B, Ferguson C, Hall T, Haqqani HM *et al*: **National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018**. *The Medical journal of Australia* 2018, **209**(8):356-362.
26. British Columbia Guidelines and Protocols Advisory Committee: **Use of non-vitamin K antagonist oral anticoagulants in non-valvular atrial fibrillation**. In. Edited by Association BCM. Victoria, BC: Guidelines and Protocols Advisory Committee; 2015.
27. British Columbia Guidelines and Protocols and Advisory Committee: **Atrial Fibrillation - diagnosis and management**. In. Edited by Association BCM. Victoria, BC: Guidelines and Protocols Advisory Committee; 2015.
28. Bruins Slot KM, Berge E: **Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation**. *The Cochrane database of systematic reviews* 2018, **3**:Cd008980.

29. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P: **2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.** *European heart journal* 2012, **33**(21):2719-2747.
30. Canadian Pharmacists Association: **Beta-adrenergic Blocking Agents [CPHA monograph]**. In: *RxTx*. Ottawa, ON; 2014.
31. Concordia Pharmaceuticals Inc: **Lanoxin (digoxin)**. In: *US Product Monograph*. St. Michael, Barbados; 2018.
32. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J *et al*: **Dabigatran versus warfarin in patients with atrial fibrillation.** *The New England journal of medicine* 2009, **361**(12):1139-1151.
33. Crowther MA, Ginsberg JB, Kearon C, Harrison L, Johnson J, Massicotte MP, Hirsh J: **A randomized trial comparing 5-mg and 10-mg warfarin loading doses.** *Archives of internal medicine* 1999, **159**(1):46-48.
34. Daiichi Sankyo Co: **Savaysa (edoxaban)**. In: *US Product Monograph*. Basking Ridge, NJ; 2017.
35. DiDomenico RJ, Bress AP, Na-Thalang K, Tsao YY, Groo VL, Deyo KL, Patel SR, Bishop JR, Bauman JL: **Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure.** *Pharmacotherapy* 2014, **34**(11):1121-1131.
36. **Pharmacogenomics guidelines** [<https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf>]
37. Ebell MH: **Evidence-based initiation of warfarin (Coumadin).** *American family physician* 2005, **71**(4):763-765.
38. Eon Labs Inc: **Bisoprolol**. In: *US Product Monograph*. Princeton, NJ; 2016.
39. ER Squibb & Sons LLC: **Eliquis (apixaban)**. In: *US Product Monograph*. Princeton, NJ; 2018.
40. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE *et al*: **2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.** *Circulation* 2011, **123**(10):e269-367.
41. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE *et al*: **Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.** *Clinical pharmacology and therapeutics* 2008, **84**(3):326-331.
42. GD Searle LLC Division of Pfizer Inc: **Calan SR (verapamil hydrochloride)**. In: *US Product Monograph*. NY, NY; 2019.

43. Gillis AM, Verma A, Talajic M, Nattel S, Dorian P: **Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.** *The Canadian journal of cardiology* 2011, **27**(1):47-59.
44. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J *et al*: **Edoxaban versus warfarin in patients with atrial fibrillation.** *The New England journal of medicine* 2013, **369**(22):2093-2104.
45. GlaxoSmithKline LLC: **Coreg (carvedilol).** In: *US Product Monograph*. Research Triangle Park, NC; 2017.
46. Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, Larue S, Langlois N, Lazo-Langner A, Zou G, Roden DM *et al*: **Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.** *Blood* 2011, **118**(11):3163-3171.
47. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A *et al*: **Apixaban versus warfarin in patients with atrial fibrillation.** *The New England journal of medicine* 2011, **365**(11):981-992.
48. Gutierrez C, Blanchard DG: **Atrial fibrillation: diagnosis and treatment.** *American family physician* 2011, **83**(1):61-68.
49. Hamadeh IS, Langaee TY, Dwivedi R, Garcia S, Burkley BM, Skaar TC, Chapman AB, Gums JG, Turner ST, Gong Y *et al*: **Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.** *Clinical pharmacology and therapeutics* 2014, **96**(2):175-181.
50. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J: **Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy.** *Annals of internal medicine* 1997, **126**(2):133-136.
51. Hauk L: **Newly Detected Atrial Fibrillation: AAFP Updates Guideline on Pharmacologic Management.** *American family physician* 2017, **96**(5):332-333.
52. Healey JS: **Stroke Prevention in Atrial Fibrillation: What Is Real World, and What Do Real-World Data Reveal?** *Journal of the American College of Cardiology* 2018, **72**(2):154-155.
53. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P: **European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.** *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* 2013, **15**(5):625-651.
54. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, John A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M *et al*: **Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.** *Proceedings of the National Academy of Sciences of the United States of America* 2000, **97**(7):3473-3478.

55. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH: **Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.** *Chest* 2012, **141**(2 Suppl):e152S-184S.
56. Honda M, Ogura Y, Toyoda W, Taguchi M, Nozawa T, Inoue H, Hashimoto Y: **Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers.** *Biological & pharmaceutical bulletin* 2006, **29**(4):772-778.
57. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE: **Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.** *The New England journal of medicine* 2003, **349**(11):1019-1026.
58. Janssen Pharmaceuticals Inc: **Xarelto (rivaroxaban).** In: *US Product Monograph.* Titusville, NJ; 2018.
59. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr., Conti JB, Ellinor PT, Ezekowitz MD, Field ME *et al*: **2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.** *Journal of the American College of Cardiology* 2014, **64**(21):e1-76.
60. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Jr., Ellinor PT, Ezekowitz MD, Field ME, Furie KL *et al*: **2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.** *Heart rhythm : the official journal of the Heart Rhythm Society* 2019, **16**(8):e66-e93.
61. Jin SK, Chung HJ, Chung MW, Kim JI, Kang JH, Woo SW, Bang S, Lee SH, Lee HJ, Roh J: **Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers.** *Journal of clinical pharmacy and therapeutics* 2008, **33**(5):567-573.
62. Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA *et al*: **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.** *Clinical pharmacology and therapeutics* 2017, **102**(3):397-404.
63. Jusko WJ, Szeffler SJ, Goldfarb AL: **Pharmacokinetic design of digoxin dosage regimens in relation to renal function.** *Journal of clinical pharmacology* 1974, **14**(10):525-535.
64. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB *et al*: **A pharmacogenetic versus a clinical algorithm for warfarin dosing.** *The New England journal of medicine* 2013, **369**(24):2283-2293.
65. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J *et al*: **2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.** *European heart journal* 2016, **37**(38):2893-2962.

66. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ *et al*: **Estimation of the warfarin dose with clinical and pharmacogenetic data.** *The New England journal of medicine* 2009, **360**(8):753-764.
67. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P *et al*: **Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis.** *Lancet (London, England)* 2014, **384**(9961):2235-2243.
68. Koup JR, Jusko WJ, Elwood CM, Kohli RK: **Digoxin pharmacokinetics: role of renal failure in dosage regimen design.** *Clinical pharmacology and therapeutics* 1975, **18**(1):9-21.
69. Kovacs MJ, Rodger M, Anderson DR, Morrow B, Kells G, Kovacs J, Boyle E, Wells PS: **Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.** *Annals of internal medicine* 2003, **138**(9):714-719.
70. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S *et al*: **Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein.** *Clinical pharmacology and therapeutics* 2002, **72**(2):209-219.
71. Li S, Lin H, Sun W, Wang Y, Ding Y, Zhao H, Liu S: **A meta-analysis of the effect of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of metoprolol.** *International journal of clinical pharmacology and therapeutics* 2017, **55**(6):483-492.
72. Luzum JA, Sweet KM, Binkley PF, Schmidlen TJ, Jarvis JP, Christman MF, Sadee W, Kitzmiller JP: **CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.** *Pharmaceutical research* 2017, **34**(8):1615-1625.
73. Macle L, Cairns J, Leblanc K, Tsang T, Skanes A, Cox JL, Healey JS, Bell A, Pilote L, Andrade JG *et al*: **2016 Focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.** *The Canadian journal of cardiology* 2016, **32**(10):1170-1185.
74. Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA: **Meta-Analysis of Direct-Acting Oral Anticoagulants Compared With Warfarin in Patients >75 Years of Age.** *The American journal of cardiology* 2019, **123**(12):2051-2057.
75. Mylan Pharmaceuticals ULC: **Verapamil.** In: *CA Drug Monograph*. Etobicoke, ON; 2009.
76. Mylan Pharmaceuticals ULC: **Mylan-carvedilol.** In: *CA Product Monograph*. Etobicoke, ON; 2017.
77. Mylan Pharmaceuticals ULC: **Verapamil hydrochloride sustained-release.** In: *CA Product Monograph*. Etobicoke, ON; 2017.
78. National Institute for Health and Clinical Excellence: **Atrial Fibrillation: management [NICE guideline CG180].** In.; 2014.
79. Nikolaidou T, Channer KS: **Chronic atrial fibrillation: a systematic review of medical heart rate control management.** *Postgraduate medical journal* 2009, **85**(1004):303-312.

80. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, 3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O'Gara PT *et al*: **2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines**. *Journal of the American College of Cardiology* 2017, **70**(2):252-289.
81. Novartis Pharmaceuticals Canada Inc: **Lopresor (metoprolol)**. In: *CA Product Monograph*. Dorval, QC; 2016.
82. Ouyang AJ, Lv YN, Zhong HL, Wen JH, Wei XH, Peng HW, Zhou J, Liu LL: **Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation**. *The American journal of cardiology* 2015, **115**(7):901-906.
83. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP *et al*: **Rivaroxaban versus warfarin in nonvalvular atrial fibrillation**. *The New England journal of medicine* 2011, **365**(10):883-891.
84. Pendopharm Division of Pharmascience Inc: **Toloxin (digoxin)**. In: *CA Product Monograph*. Montreal, QC; 2016.
85. Pfizer Canada Inc: **Inderal-LA (propranolol)**. In: *CA Product Monograph*. Kirkland, QC; 2012.
86. Pfizer Canada Inc: **Inderal-LA (propranolol)**. In: *CA Product Monograph*. Kirkland, QC; 2016.
87. Pfizer Canada Inc: **Propranolol**. In: *CA Product Monograph*. Kirkland, QC; 2016.
88. Pfizer Canada Inc: **Eliquis (apixaban)**. In: *CA Product Monograph*. Kirkland, QC; 2018.
89. Pfizer Canada ULC: **Eliquis (apixaban)**. In: *CA Product Monograph*. Kirkland, QC; 2011.
90. Pfizer Laboratories Div Pfizer Inc: **Corgard (nadolol)**. In: *US Product Monograph*. NY, NY; 2013.
91. Pokorney SD, Gersh BJ, Ahmad A, Al-Khatib SM, Blank M, Coylewright M, DiBattiste P, Healey JS, Hedrich O, Hylek EM *et al*: **Stroke prevention in atrial fibrillation: Closing the gap**. *American heart journal* 2019, **210**:29-38.
92. Poulussen FCP, Peters BJ, Hua KH, Houthuizen P, Grouls RJ, Deenen MJ: **The effect of the CYP2D6 genotype on the maintenance dose of metoprolol in a chronic Dutch patient population**. *Pharmacogenetics and genomics* 2019, **29**(7):179-182.
93. Richards D: **Guidance on converting between anticoagulants**. In: Gloucestershire Hospitals: NHS Foundation Trust; 2015.
94. Ryu RJ, Eyal S, Easterling TR, Caritis SN, Venkataraman R, Hankins G, Rytting E, Thummel K, Kelly EJ, Risler L *et al*: **Pharmacokinetics of metoprolol during pregnancy and lactation**. *Journal of clinical pharmacology* 2016, **56**(5):581-589.
95. Servier Canada Inc.: **Lixiana (edoxaban tosylate monohydrate)**. In: *CA Product monograph*. Laval, Quebec; 2017.
96. Sivem Pharmaceuticals ULC: **Amiodarone**. In: *CA Product Monograph*. St. Laurent, QC; 2016.

97. Sivem Pharmaceuticals ULC: **Carvedilol** In: *CA Product Monograph*. St Laurent, QC; 2018.
98. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ *et al*: **Pharmacogenetics: from bench to byte--an update of guidelines**. *Clinical pharmacology and therapeutics* 2011, **89**(5):662-673.
99. Taguchi M, Nozawa T, Mizumaki K, Inoue H, Tahara K, Takesono C, Hashimoto Y: **Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in routinely treated Japanese patients**. *Biological & pharmaceutical bulletin* 2004, **27**(10):1642-1648.
100. Takekuma Y, Takenaka T, Kiyokawa M, Yamazaki K, Okamoto H, Kitabatake A, Tsutsui H, Sugawara M: **Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis**. *Biological & pharmaceutical bulletin* 2007, **30**(3):537-542.
101. Teva Canada Ltd: **Propranolol**. In: *CA Product Monograph*. Toronto, ON; 2011.
102. Upsher-Smith Laboratories Inc: **Pacerone (amiodarone)**. In: *US Product Monograph*. Maple Grove, MN; 2017.
103. Valeant Pharmaceuticals North America LLC: **Cardizem LA (diltiazem)**. In: *US Product Monograph*. Steinbach, MB; 2016.
104. Valeant Pharmaceuticals North America LLC: **Cardizem CD (diltiazem)**. In: *US Product Monograph*. Steinbach, MB; 2017.
105. Validus Pharmaceuticals LLC: **Lopressor (metoprolol)**. In: *US Product Monograph*. Parsippany, NJ 2017.
106. Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, McMurtry MS, Connolly S, Cox JL, Dorian P *et al*: **2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation**. *The Canadian journal of cardiology* 2014, **30**(10):1114-1130.
107. Wann LS, Curtis AB, Ellenbogen KA, Estes NA, 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ *et al*: **2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines**. *Journal of the American College of Cardiology* 2011, **57**(11):1330-1337.
108. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA, 3rd, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM *et al*: **2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines**. *Heart rhythm : the official journal of the Heart Rhythm Society* 2011, **8**(1):157-176.
109. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE: **Pharmacogenomics knowledge for personalized medicine**. *Clinical pharmacology and therapeutics* 2012, **92**(4):414-417.

110. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A *et al*: **Antithrombotic therapy for atrial fibrillation with stable coronary disease**. *The New England journal of medicine* 2019, **381**(12):1103-1113.
111. Zineh I, Beitelshes AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA: **Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension**. *Clinical pharmacology and therapeutics* 2004, **76**(6):536-544.